![CMT Research Foundation Invests in ReviR Therapeutics Research to Pioneer Small Molecule Therapeutics for CMT1A](https://cmtrf.org/wp-content/uploads/2024/06/ReviR-1080x512.png)
![CMT Research Foundation Invests in ReviR Therapeutics Research to Pioneer Small Molecule Therapeutics for CMT1A](https://cmtrf.org/wp-content/uploads/2024/06/ReviR-1080x512.png)
![CMT Research Foundation Invests in Project to Test if a Commercially Available Drug is Effective Treatment for X-linked Charcot-Marie-Tooth Disease](https://cmtrf.org/wp-content/uploads/2024/04/Abrams.png)
CMT Research Foundation Invests in Project to Test if a Commercially Available Drug is Effective Treatment for X-linked Charcot-Marie-Tooth Disease
The CMT Research Foundation (CMTRF), a non-profit focused solely on delivering treatments and cures for Charcot-Marie-Tooth disease (CMT), has invested in a project led by Dr. Charles Abrams, a Professor in the Department of Neurology and Rehabilitation at the...![CMT Research Update/NMD Pharma](https://cmtrf.org/wp-content/uploads/2024/04/nmdpharma_logo.jpeg)
CMT Research Update/NMD Pharma
NMD Pharma recently published data demonstrating that their drug candidate, NMD670, improves muscle function and neuromuscular transmission deficits in both animal models and patients. Dr. William David Arnold, a member of the CMTRF Scientific Advisory Board, who was...Updates on CMT Research
There have been a number of interesting developments in CMT research in the past few weeks. Here are three: Update 1: Pharnext recently announced topline results of its pivotal phase 3 (PREMIER trial) of PXT3003, its drug candidate for Charcot-Marie-Tooth 1A (CMT1A)...![ARM-101: A Potential “Precision Drug Therapy” For CMT1A](https://cmtrf.org/wp-content/uploads/2023/10/Armatus-logo-RGB_May-1-1080x624.jpg)